- ImmuCell Corp., of Portland, Maine, received a $507,000 Phase IISmall Business Innovation Research grant from the National Instituteof Allergy and Infectious Diseases. The funding will be used to supportdevelopment of a passive antibody product for the treatment ofcrytosopridiosis in AIDS patients.- Cypros Pharmaceutical Corp., of Carlsbad, Calif., received a$460,000, two-year Phase II Small Business Innovation Research grantfrom the National Institutes of Health for funding the development ofneuronal calcium channel-blocking drugs for treating neurologic andpsychiatric diseases.- Unigene Laboratories Inc., of Fairfield, N.J., is extending theexpiration date of its class B warrants by one year, to Aug. 11, 1995. Aclass B warrant is exercisable at $5 for one share of common stock.- Mediscience Technology Corp., of Cherry Hill, N.J. completed theprivate placement of Phase I of its $4 million to $6 million financingpackage for more than $1 million, which was coordinated by CobyCapital Corp. The company said completion of Phase II of theplacement will allow NASDAQ listing for Mediscience.

(c) 1997 American Health Consultants. All rights reserved.

No Comments